References
- Akiyama, H., Haga, Y., Sasaki, N., Yanagisawa, T., & Hasegawa, Y. (2014). A case of rhabdomyolysis in which levetiracetam was suspected as the cause. Epilepsy & Behavior Case Reports, 2, 152–6. https://doi.org/https://doi.org/10.1016/j.ebcr.2014.08.001
- Aslan, N., Yildizdas, D., Huseyınlı, B., Horoz, O. O., Mert, G. G., Ekinci, F., & Ozcanyuz, D. (2020). Levetiracetam treatment-associated acute rhabdomyolysis in an adolescent. Journal of Pediatric Intensive Care, 09(2), 139–140. https://doi.org/https://doi.org/10.1055/s-0039-1700951
- Brodie, M. J. (2010). Antiepileptic drug therapy the story so far. Seizure, 19(10), 650–655. https://doi.org/https://doi.org/10.1016/j.seizure.2010.10.027
- Chakkalakal, J. V., Nishimune, H., Ruas, J. L., Spiegelman, B. M., & Sanes, J. R. (2010). Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons. Development, 137(20), 3489–3499. https://doi.org/https://doi.org/10.1242/dev.053348
- Di Lorenzo, R., & Li, Y. (2017). Rhabdomyolysis associated with levetiracetam administration: Levetiracetam and rhabdomyolysis. Muscle & Nerve, 56(1), E1–E2. https://doi.org/https://doi.org/10.1002/mus.25548
- Elsayed, E. F., & Reilly, R. F. (2010). Rhabdomyolysis: A review, with emphasis on the pediatric population. Pediatric Nephrology, 25(1), 7–18. https://doi.org/https://doi.org/10.1007/s00467-009-1223-9
- Gidal, B. E., Baltès, E., Otoul, C., & Perucca, E. (2005). Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trials. Epilepsy Research, 64(1–2), 1–11. https://doi.org/https://doi.org/10.1016/j.eplepsyres.2005.01.005
- Incecik, F., Herguner, O. M., Besen, S., & Altunbasak, S. (2016). Acute rhabdomyolysis associated with levetiracetam therapy in a child. Acta Neurologica Belgica, 116(3), 369–370. https://doi.org/https://doi.org/10.1007/s13760-015-0542-9
- Isaacson, J. E., Choe, D. J., & Doherty, M. J. (2014). Creatine phosphokinase elevation exacerbated by levetiracetam therapy. Epilepsy & Behavior Case Reports, 2, 189–191. https://doi.org/https://doi.org/10.1016/j.ebcr.2014.09.008
- Kim, H., Jo, S., Park, K. W., Han, S. H., & Lee, S. A. (2016, June 30). A case of phenytoin-induced rhabdomyolysis in status epilepticus. Journal of Epilepsy Research, 6(1), 36–38. https://doi.org/https://doi.org/10.14581/jer.16007
- Kubota, K., Yamamoto, T., Kawamoto, M., & Fukao, T. (2017). Levetiracetam-induced rhabdomyolysis: A case report and literature review. Neurol Asia, 22(3), 275-278. http://neurology-asia.org/articles/neuroasia-2017-22(3)-275.pdf
- Moinuddin, I. A. (2020, October 28). Suspected levetiracetam-induced rhabdomyolysis: A case report and literature review. American Journal of Case Reports, 21, e926064. https://doi.org/https://doi.org/10.12659/AJCR.926064. PMID: 33112844; PMCID: PMC7603803.
- Otoul, C., De Smedt, H., & Stockis, A. (2007). Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia, 48(11), 2111–2115. https://doi.org/https://doi.org/10.1111/j.1528-1167.2007.01201.x
- Ramon, M., Tourteau, E., Lemaire, N., Gautier, S., & Béné, J. (2016). HyperCKemia induced by levetiracetam. La Presse Médicale, 45(10), 943–944. https://doi.org/https://doi.org/10.1016/j.lpm.2016.05.014
- Rastogi, V., Singh, D., Kaur, B., Arora, P., & Gadikota, J. P. (2018). Rhabdomyolysis: A rare adverse effect of levetiracetam. Cureus, 10(5), e2705. Published online May 29. https://doi.org/https://doi.org/10.7759/cureus.2705.
- Rota, E., Arena, L., Celli, L., Testa, L., & Morelli, N. (2018). Levetiracetam-induced rhabdomyolysis: The first Italian case. Neurological Sciences, 39(9), 1629–1630. https://doi.org/https://doi.org/10.1007/s10072-018-3421-3
- Shahbaz, N., Khan, S. A., Younus, S. M., Khan, M. A., & Memon, M. H. (2017). Levetiracetam induced increase in creatine Phosphokinase levels. Journal of the College of Physicians and Surgeons--pakistan, 27(3), S63-S64. https://pubmed.ncbi.nlm.nih.gov/28302251/
- Singh, R., Patel, D. R., & Pejka, S. (2014). Rhabdomyolysis in a hospitalized 16-year-old boy: A rarely reported underlying cause. Case Reports in Pediatrics, 2, 1–2. https://doi.org/https://doi.org/10.1016/j.ebcr.2014.09.008
- Sohn, S.-Y., Kim, J. G., Kim, D.-H., Jang, S.-H., Yoon, S. J., & Lee, S. J. (2017). Repeated occurrence of HyperCKemia after levetiracetam administration. Published online. 5, 150-154. https://www.ecronicon.com/ecne/pdf/ECNE-08-00250.pdf
- Steinhoff, B. J., Trinka, E., & Wieser, H.-G. (2005). Levetiracetam in patients with refractory epilepsy: Results of the SKATE trial in Austria, Germany and Switzerland. Seizure, 14(7), 490–496. https://doi.org/https://doi.org/10.1016/j.seizure.2005.08.005
- Thomas, L., Mirza, M. M. F., Shaikh, N. A., & Ahmed, N. (2019). Rhabdomyolysis: A rare adverse effect of levetiracetam. BMJ Case Reports, 12(8), e230851. https://doi.org/https://doi.org/10.1136/bcr-2019-230851
- Toth, P. P., Patti, A. M., Giglio, R. V., Nikolic, D., Castellino, G., Rizzo, M., & Banach, M. (2018). Management of statin intolerance in 2018: Still more questions than answers. American Journal of Cardiovascular Drugs, 18(3), 157–173. https://doi.org/https://doi.org/10.1007/s40256-017-0259-7